USE OF NKG2A ANTIBODIES FOR TREATMENT OF BONE LOSS

• Main Authors: SODERSTROM, KALLE, GALSGAARD, ELISABETH DOUGLAS
• Format: Patent
• Language: English; French
• Published: 21.07.2020
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular, the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis, or rheumatic arthritis with anti-NKG2A antibodies, examples of which include known antibodies such as humanized versions of Z199 and Z270. It is shown herein that anti-NKG2A antibodies can cause NK cells to lyse osteoclasts and fibroblast-like synoviocytes (FLS) from RA patients' synovium and that treatment with anti-NKG2A antibody suppresses bone erosion in cultured cells, tissue explant cultures, or tissue shavings of explants from RA patients. La présente invention concerne le traitement de maladies caractérisées par la destruction du cartilage et/ou l'érosion osseuse. L'invention se rapporte en particulier au traitement de l'ostéoarthrite, de l'ostéoporose, de l'arthrite psoriasique ou de l'arthrite rhumatismale par un anticorps anti-NKG2A.